Matinas Biopharma Holdings Inc [AMEX: MTNB] price surged by 43.03 percent to reach at $0.71.
A sum of 22471117 shares traded at recent session while its average daily volume was at 259.00K shares. Matinas Biopharma Holdings Inc shares reached a high of $3.09 and dropped to a low of $1.64 until finishing in the latest session at $2.36.
The one-year MTNB stock forecast points to a potential upside of 92.13. The average equity rating for MTNB stock is currently 2.00, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Matinas Biopharma Holdings Inc [MTNB]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MTNB shares is $30.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MTNB stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Piper Sandler have made an estimate for Matinas Biopharma Holdings Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on May 11, 2021. While these analysts kept the previous recommendation, Piper Sandler raised their target price to Overweight. The new note on the price target was released on August 26, 2020, representing the official price target for Matinas Biopharma Holdings Inc stock. Previously, the target price had yet another raise to $3, while Piper Sandler analysts kept a Overweight rating on MTNB stock.
The Price to Book ratio for the last quarter was 1.56, with the Price to Cash per share for the same quarter was set at 1.29.
MTNB Stock Performance Analysis:
Matinas Biopharma Holdings Inc [MTNB] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 108.85. With this latest performance, MTNB shares gained by 145.83% in over the last four-week period, additionally plugging by 293.33% over the last 6 months – not to mention a rise of 362.75% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MTNB stock in for the last two-week period is set at 86.62, with the RSI for the last a single of trading hit 0.34, and the three-weeks RSI is set at 0.21 for Matinas Biopharma Holdings Inc [MTNB]. The present Moving Average for the last 50 days of trading for this stock 1.01, while it was recorded at 1.73 for the last single week of trading, and 0.74 for the last 200 days.
Matinas Biopharma Holdings Inc (MTNB) Capital Structure & Debt Analysis
According to recent financial data for Matinas Biopharma Holdings Inc. ( MTNB), the Return on Equity (ROE) stands at -146.46%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -109.58%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Matinas Biopharma Holdings Inc’s Return on Invested Capital (ROIC) is -208.98%, showcasing its effectiveness in deploying capital for earnings.
Matinas Biopharma Holdings Inc (MTNB) Efficiency & Liquidity Metrics
Based on Matinas Biopharma Holdings Inc’s (MTNB) latest financial statements, the Debt-to-Equity Ratio is 0.33%, indicating its reliance on debt financing relative to shareholder equity.
Matinas Biopharma Holdings Inc (MTNB) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Matinas Biopharma Holdings Inc. (MTNB) effectively leverages its workforce, generating an average of -$2801428.57 per employee. The company’s liquidity position is robust, with a Current Ratio of 4.07% and a Quick Ratio of 4.07%, indicating strong ability to cover short-term liabilities.
MTNB Stock EPS
With the latest financial reports released by the company, Matinas Biopharma Holdings Inc posted -0.81/share EPS, while the average EPS was predicted by analysts to be reported at -0.78/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.03. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MTNB.
Matinas Biopharma Holdings Inc [MTNB] Institutonal Ownership Details
There are presently around $5.68%, or 6.47%% of MTNB stock, in the hands of institutional investors. The top three institutional holders of MTNB stocks are: HIGHBRIDGE CAPITAL MANAGEMENT LLC with ownership of 10.64 million shares, which is approximately 4.2688%. VANGUARD GROUP INC, holding 9.32 million shares of the stock with an approximate value of $$1.48 million in MTNB stocks shares; and VANGUARD GROUP INC, currently with $$0.55 million in MTNB stock with ownership which is approximately 1.4004%.
